Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (November 2017)
25 slides from Clearpoint Neuro's investor presentation, Nov 6, 2017
Slide 1: Investor Presentation November 2017
NS ™__ INTERVENTIONS Investor Presentation November 2017 (© 2017 MRIINTERVENTIONS,INC. | 4
Slide 2: Forward Looking Statements
SE — Forward Looking Statements herein ing MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as
Slide 3: MRIC: The Platform Company for MRI-Guided Therapies
MRIC: The Platform Company for MRI-Guided Therapies MRI Interventions: Leader in the Delivery of MRI-Guided Therapies + Primary Innovator in the Field, grown out of the Advanced MR department at Johns Hopkins Extensive Intellectual Property position: 70+ issued US patents, 45 international Proven tr
Slide 4: Our MRI-Guided Therapy Platform is Currently Being Used to
Our MRI-Guided Therapy Platform is Currently Being Used to: Implant Neuro Stimulation Products from: * Medtronic * St. Jude Medical * NeuroPace Place Laser Ablation Probes from: + Medtronic-Visualase + Monteris Medical Deliver Drugs and Biologics from: + Voyager * Medicenna + Oxford Biomedica + Inte
Slide 5: Broad and Growing User Base of Leading Neurosurgeons
SS Broad and Growing User Base of Leading Neurosurgeons ClearPoint” Is Installed in 52 Top US Hospitals and Growing uc San Francisco Brigham & Women's ‘San Francisco VA Boston children’s ‘Stanford Univ Yale Uni UCSF Benioff childrens Univ of Pitt Med Center ‘Memorial Sioan Ketterin UC San Diego Hack
Slide 6: Foundation of Our Platform
Foundation of Our Platform: ClearPoint Neuro Navigation System (© 2017 MRIINTERVENTIONS, INC. | 6
Slide 7: Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed Blind
Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed “Blind” fat Stereotactic Procedure ClearPoint Neuro Procedure
Slide 8: ClearPoint Neuro Navigation System
ClearPoint Neuro Navigation System: MRI-Guided NeuroSurgical Platform ClearPoint Components: Capital Sale Recurring Revenue Reusable Hardware Components Integrated Software Single-Use, Disposable Components Univ of California San Francisco Univ of Pittsburgh Medical Center Medical Center © 2017 MRLI
Slide 9: Details on Our ClearPoint Neuronavigation System Platform
Details on Our ClearPoint Neuronavigation System Platform ClearPoint Procedure Overview: ClearPoint Video ClearPoint Video Entry and Trajectory Alignment and Insertion © 2017 MLINTERVENTIONS, INC. | 9
Slide 10: Multiple Clinical Applications for Our ClearPoint System
Multiple Clinical Applications for Our ClearPoint System MRI-Guided Therapy Platform Delivering Therapies to Address Significant Unmet Medical Needs ~ Parkinson’s disease, Epilepsy, Brain Tumor, Dystonia Enabling Multiple Therapies from Multiple Companies: — Electrode Placement: Medtronic, St. Jude,
Slide 11: Strong Business Model for Our Core MRI-Guided Navigation Platform
Strong Business Model for Our Core MRI-Guided Navigation Platform = ClearPoint Hardware/Software: $100,000 - $150,000 ASP = ClearPoint Disposables: ~$7,500 ASP per procedure with strong margins = Recurring revenue from the sale of disposables = Procedures covered by existing inpatient DRG reimbursem
Slide 12: ClearPoint Neurosurgical Procedure Growth
SS —— ClearPoint Neurosurgical Procedure Growth 800 700 Procedures 625-675 CAGR, 2013 — 2016: 46% (iz) 600 * Qi, 2017: 500 146 Procedures 400 Q2, 2017: 162 Procedures 200 Q3, 2017: 100 | 161 Procedures 0 2013 2015 2016 2017 Outlook {© 2017 MRI INTERVENTIONS, INC
Slide 13: Expanding Our Platform
Expanding Our Platform: New Procedural Applications {© 2017 MRIINTERVENTIONS, INC. 13,
Slide 14: Expanding MRIC's MRI-Guided Therapy Platform
Expanding MRIC’s MRI-Guided Therapy Platform Benefits Larger Patient Populations lished the Capability of the Platform... ¥ Began with Electrode Placement (DBS) ~ Parkinson's disease, dystonia ¥ Expanded to Biopsy — Brain Tumor ¥ Expanded to Laser Ablation Probe Placement — Epilepsy and Brain Tumor
Slide 15: Expanding into the Stroke Market
Expanding into the Stroke Market Leveraging Existing Capabilities and Install Base Expanding the Reach of the MRIC Platform into the Stroke Market + Joint Development Agreement with Mayo Clinic * Dr. Bernard Bendok, Chair of Neurosurgery, Mayo Arizona Large Stroke Market + Sth leading cause of death
Slide 16: Our MRI-Guided Approach to Intra Cerebral Hemorrhagic Stroke
Our MRI-Guided Approach to Intra Cerebral Hemorrhagic Stroke Current for Removal and ion are * Open craniotomy provides visibility but is highly invasive, destroys brain tissue + Minimally Invasive approach has very limited ability to quantify volume reduction of the hemorrhage or monitor subsequent
Slide 17: Expanding our Platform with a Novel Ablation Technology
Expanding our Platform with a Novel Ablation Technology Co-Development Agreement Will Add Additional Capabilities License and C with Acoustic (AMS) * Leading developer of ultrasound ablation technologies and systems + Base technology has 510k clearance + Initial license areas: WW Excl. for Pancreati
Slide 18: Strong Pipeline of New Products to Add to our Existing Platform
Strong Pipeline of New Products to Add to our Ex’ Leveraging our MRI-Guided Therapy Platform Jew Products in Development kaearPoin software 2.0 kicrPoin Org DetiveryCannula CE Mark IearAway™ Intracerebral Hemorrhage earAbate™ ~ Pancreas/iver (Gen 3) IearAbate™ ~ Pancreas (Gen2) Jorug Trial in Progre
Slide 19: Addressable Markets for our MRI-Guided Therapy Platform
Addressable Markets for our MRI-Guided Therapy Platform Prevalence | 1,500,000 | 2,200,000 | 0.000 90,000 50,000 1500.00 | 20,000 Nee | 12500 28,000 15,000 13,500 12,500 25,000, 26,000, st Average Salling pee | 57500 $7,500 $7,500 $6,000 $5,000 $14,000, $8,000 ‘Annual Market tun Growing Ci 24% Month
Slide 20: Financials
Financials (© 2017 MRIINTERVENTIONS INC. 120
Slide 21: Growth
Growth A $7,000,000 $6,000,000 $5,000,000 $4,000,000 $3,000,000 $2,000,000 $1,000,000 & Total Revenue 201320182015 2016 Qu-3 2017 Consumables m Capital / Service m Other Disposable Product Estimated CAGR: 30% a Results of Note: Installed at 52 of 250+ target US neurosurgery centers H1 2017 revenue o
Slide 22: Cash Flow From Operations: 2015 - Q2, 2017
eS Cash Flow From Operations*: 2015 — Q2, 2017 $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Qi Q2 Q3 Q4 Ql Q2 Q3 Q4 Ql Q2 a3 2015 2016 2017 2017 MRIINTERVENTIONS, INC, | 22
Slide 23: Income Statement, Last Quarters
Income Statement, Last 5 Quarters Revenues: Disposable product revenues $ 1272 $ 1363 $1,663 $1436 $ 1,421 Reusable product revenues Total product revenues 1581 15871922 1,893 1,629 Service revenues 35 48 85 3 88 Total revenues 1616 16352007 «1976 ~«1,717, Cost of product revenues 748 677___752 798
Slide 24: Experienced Medical Device Management Team
Experienced Medical Device Management Team Management Team Joseph Burnett. CEO EQ Muovcana shesihc Peter Piferi coo Wendelin Maners. VP Sales & Mrktg Hal Hurwitz CFO Board of Directors Kimble senkins, | Mara Sain Joha Fletcher Pascal iin Ti Jack Spencer Chairman canrouneric ‘weigh. chars ewsratonc «
Slide 25: Summary
EE —— Summary Significant Value in Owning the MRI-Guided Therapy Platform Leader in this Field - Primary Innovator, Established Clinical Footprint, Industry Integration, IP World-Class Research Institutions Behind All Major Initiatives Proven Ability to Develop, Commercialize and Secure Clinical Ado
MRI Interventions — Investor Presentation (November 2017) on 6ix